IPSEN SA: directors' dealings · France · AMF

About IPSEN SA

Ipsen SA is a French biopharmaceutical group listed in Paris under ISIN FR0010259150. The company develops and markets specialty medicines focused on three core therapeutic areas: oncology, rare disease, and neuroscience. Ipsen is positioned as a niche, science-driven healthcare company that relies on external innovation, clinical development, and global partnerships to expand its portfolio. In its most recent public communications, the group states that its medicines are available in more than 80 countries and that it operates through teams in more than 40 countries, supported by major hubs in France, the United States, and the United Kingdom. Ipsen’s roots go back nearly a century, and the company has evolved from a French industrial base into an international specialty biopharma business. Over time, it has built a reputation around prescription medicines addressing highly targeted medical needs rather than mass-market products. That strategic positioning has been reinforced by sustained investment in research and development, a strong emphasis on licensing and partnerships, and selective business development to add differentiated assets to the pipeline. The company’s product portfolio spans several well-known specialty medicines and development programs. Ipsen highlights a broad platform in oncology, rare diseases, and neuroscience, with a business model centered on specialty products that can generate durable value through lifecycle management, label expansion, and regulatory milestones. Recent corporate updates indicate continued momentum across the pipeline, supported by product launches, clinical progress, and approvals that help refresh the growth profile of the group. Geographically, Ipsen is truly global. Although headquartered in France, the group derives a substantial portion of its activity outside its home market through a worldwide commercial organization and partnerships that extend its reach. Ipsen says it has products registered in more than 80 countries and around 5,000 employees worldwide, underlining its scale as a mid-sized but internationally relevant pharmaceutical company. The company also regularly publishes its Universal Registration Document and annual reports, reflecting a structured governance framework and a disciplined approach to investor communication. A notable recent development is Ipsen’s continued expansion through external innovation and regulatory execution. In April 2026, the company announced a conditional marketing authorization in Europe for Ojemda® in a rare pediatric indication, illustrating its ability to convert research and partnerships into commercial opportunities. Overall, Ipsen stands out as a specialized French healthcare group combining therapeutic focus, global reach, and a steady pipeline-led growth strategy.